



Transfer of securities to BNP Paribas Arbitrage Issuance B.V. (“BNPP IBV”) pursuant to Part VII of the UK Financial Services and Markets Act 2000

On 19 November 2015, The Royal Bank of Scotland plc (with its registered office at 36 St Andrew Square, Edinburgh, Scotland) (“**RBS**”) and BNP Paribas S.A. (incorporated in France and with its registered office at 16, Boulevard des Italiens, 75009 Paris, France) (“**BNPP**”), acting through its London Branch, announced that the Court of Session in Scotland had approved and sanctioned the implementation of a banking business transfer scheme, whereby certain assets and liabilities related to RBS’s structured retail investor products and equity derivatives business would be transferred to BNPP pursuant to Part VII of the UK Financial Services and Markets Act 2000 (the “**Part VII Scheme**”).

The Part VII Scheme took effect on 7 December 2015 (the “**Effective Date**”).

On the Effective Date, BNPP, acting through its London Branch, became the issuer of those securities originally issued by RBS that were transferred pursuant to the Part VII Scheme. Immediately after the transfer of those securities to BNPP, acting through its London Branch, the role of the issuer under those securities was transferred, also under the terms of the Part VII Scheme, to BNPP IBV, a wholly owned subsidiary of BNPP. As part of the Part VII Scheme, BNPP guarantees all the obligations of BNPP IBV arising in respect of the transferred securities.

Under the Part VII Scheme, amendments were made to the terms of the transferring securities and to agreements related to them from the Effective Date in order to give effect to the Part VII Scheme, including (but not limited to) references to “RBS”, in its capacity as issuer of the transferred securities, being construed as references to “BNPP IBV”.

Details of the securities that have transferred under the Part VII Scheme as well as further information on the Part VII Scheme generally can be viewed at <http://warrants.bnpparibas.com/>

Transfers of securities to RBS plc pursuant to Part VII of the UK Financial Services and Markets Act 2000

On 6 February 2010 ABN AMRO Bank N.V. (registered with the Dutch Chamber of Commerce under number 33002587) changed its name to The Royal Bank of Scotland N.V. ("**RBS N.V.**") and on 1 April 2010 ABN AMRO Holding N.V. changed its name to RBS Holdings N.V.

On 23 September 2011, RBS N.V. and The Royal Bank of Scotland plc (with its registered office at 36 St Andrew Square, Edinburgh, Scotland) ("**RBS plc**") announced that the Court of Session in Scotland had approved and sanctioned the implementation of a banking business transfer scheme whereby eligible business carried on in the United Kingdom by RBS N.V. would be transferred to RBS plc pursuant to Part VII of the UK Financial Services and Markets Act 2000 (the "**Part VII Scheme**"). The Part VII Scheme took effect on 17 October 2011 (the "**Effective Date**").

From the Effective Date, RBS plc became the issuer of those securities originally issued by RBS N.V. which were transferred to RBS plc pursuant to the Part VII Scheme. Under the Part VII Scheme, amendments were made to the terms of the transferring securities and to agreements related to them from the Effective Date in order to give effect to the Part VII Scheme, including (but not limited to) references to "RBS N.V." being construed as references to "RBS plc". Details of these amendments are set out in the Scheme Document which can be viewed at http://www.investors.rbs.com/RBS_NV.

For details of which securities were transferred to RBS plc pursuant to the Part VII Scheme, investors should refer to http://www.investors.rbs.com/RBS_NV or, for securities issued from on or about 21 July 2011, investors should refer to the terms of the issue or offer documents (including term-sheets) (if they indicate that RBS plc was expected to become the issuer of the securities as a result of the Part VII Scheme, then RBS plc has become the issuer, unless the securities have been exercised, redeemed or repurchased and cancelled prior to the implementation of the Part VII Scheme).

For further details of the Part VII Scheme generally, investors should refer to http://www.investors.rbs.com/RBS_NV.



OPEN END CERTIFICATE

(Underlying Tracking Certificate)

linked to the the AMEX Pharmaceutical Index

14 August 2002

FINAL TERMS AND CONDITIONS

We are pleased to present for your consideration the transaction described below. We are willing to negotiate a transaction with you because we understand that you have sufficient knowledge, experience and professional advice to make your own evaluation of the merits and risks of a transaction of this type and you are not relying on ABN AMRO Bank N.V. nor any of the companies in the ABN AMRO group for information, advice or recommendations of any sort other than the factual terms of the transaction. This term sheet does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering into the transaction. You should consult your own business, tax, legal and accounting advisors with respect to this proposed transaction and you should refrain from entering into a transaction with us unless you have fully understood the associated risks and have independently determined that the transaction is appropriate for you. Due to the proprietary nature of this proposal please understand that it is confidential.

| | |
|------------------|---|
| SUMMARY | <p>Issuer: ABN AMRO Bank N.V. (senior long term debt rating: Moody's Aa2, S&P AA)</p> <p>Lead Manager: ABN AMRO</p> <p>Description: An index certificate without a fixed Expiration Date that tracks the performance of the Index. Investors are entitled to exercise the Certificates on a yearly basis on specified Exercise Dates. The Issuer is entitled to terminate the Certificates upon two years notice, commencing three years after the Issue Date.</p> <p>Index: AMEX Pharmaceutical Index (Reuters Code: .DRG)</p> <p>Issue Price: USD 29.25</p> <p>Spot Reference: 292.51 (the closing level of the Index as of 30 July 2002)</p> <p>Number of Certificates Issued: 180,000</p> <p>Nominal Amount: USD 5,265,000</p> <p>Exchange(s): The exchange or quotation system where the shares that comprise the Index have their primary listing or any successor to such exchange or quotation system</p> <p>Trading Day: Any day that is a trading day for the Exchange(s) other than a day on which trading on any of the Exchange(s) is scheduled to close prior to its regular weekday closing time</p> <p>Certificate Entitlement: 10 Certificates control 1 Index</p> <p>Settlement Amount: For each Certificate duly exercised an amount equal to the level of the Index at the Valuation Time on the Valuation Date, taking into account the Certificate Entitlement.</p> <p>Exercise Date: Three business days prior to the Valuation Date</p> <p>Valuation Time: The close of trading on the relevant Exchange(s)</p> <p>Valuation Dates: The last Trading Day of March in each year, commencing March 2003 (each a "Valuation Date")</p> <p>Expiration Date: Not applicable</p> <p>Early Termination: The Issuer is entitled to terminate the Certificates on any date upon two years notice against payment of the Early Termination Amount, commencing three years after the Issue Date (the "Early Termination Date").</p> <p>Early Termination Amount: For each Certificate an amount equal to the level of the Index at the Valuation Time on the Early Termination Date, taking into account the Certificate Entitlement.</p> <p>Settlement: USD Cash Settlement in case of Early Termination or exercise</p> <p>Settlement Date: 5 business days following the Early Termination Date or Valuation Date</p> <p>Calculation Agent: ABN AMRO BANK N.V.</p> <p>Listing: SWX Swiss Stock Exchange</p> <p>Secondary Settlement: Trade Date + 3 Business Days</p> <p>Indicative Spread: 1.5 % (1% during US trading hours) under normal market circumstances)</p> <p>Minimum Trading Size: 1 Certificate</p> <p>Clearing System Trading Size: 1 Certificate</p> <p>Associated Risks: Please refer to Appendix A</p> <p>Clearing: SIS SegalIntersettle AG, Euroclear Bank SA, Clearstream Banking SA</p> <p>Security Codes: ISIN: CH0014686791 COMMON CODE: 15302984 VALOREN: 1468679</p> <p>Applicable law: English</p> <p>Symbol: DRGOE</p> <p>Quoted On: AAHCH05</p> <p>Selling restrictions: No sales permitted into the U.S. or to U.S. persons, standard U.K. and Japan selling restrictions</p> |
| Timetable | <p>Launch & Pricing Date: 07 August 2002</p> <p>Issue & Payment Date: 19 August 2002</p> <p>Listing Date: 19 August 2002</p> <p>Final Settlement Date: 5 business days after exercise or Early Termination.</p> |



This term sheet is for information purposes only and does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. All prices are indicative and dependent upon market conditions and the terms are liable to change and completion in the final documentation.

The AMEX Pharmaceutical Index is a service mark of, and is being used with the permission of, the American Stock Exchange (the "AMEX"). The AMEX in no way sponsors, endorses or is otherwise involved in the Open End Certificates. The AMEX disclaims any liability to any party for any inaccuracy in the data on which the Index is based, for any mistakes, errors, or omissions in the calculation and/or dissemination of the Index, or for the manner in which it is applied in connection with the Open End Certificates.

The AMEX Pharmaceutical Open End Certificate

Open End Certificates

A certificate without a fixed Expiration Date that tracks the performance of the AMEX Oil Index. The AMEX Pharmaceutical Index is a capitalization-weighted index designed

Main benefits at a glance

to represent a cross section of widely held, highly capitalized companies involved in various phases of the pharmaceutical industry. Investors are entitled to exercise the Certificates on a yearly basis on specified Exercise Dates. The Issuer is entitled to terminate the Certificates upon two years notice, commencing three years after the Issue Date.

Tracks the performance of the AMEX Pharmaceutical Index.
Permanent liquidity ensured by the issuer.

APPENDIX A - RISK FACTORS

An investment in the Certificates entails significant risks not associated with similar investments in a conventional debt or equity security, including the following:

1. Commodity Market Risk: Level of the Underlying

The Certificates entitle the Certificateholder of a Certificate to receive the Settlement or Early Termination Amount from the Issuer on the Settlement Date. Investors are therefore at risk that the level of the Underlying Commodity may cause the Settlement or Early Termination Amount to be less than the amount paid for the Certificates. Accordingly, this investment bears the market risk of a direct commodity investment and investors are cautioned to take advice accordingly. The historical level of the Underlying should not be taken as an indication of the Underlying's future performance during the term of the Certificates.

2. Secondary Market Risk

The price of the Certificates will be affected by a number of factors independent of the creditworthiness of the Issuer and the price of the Underlying Commodity, including, but not limited to, market interest, exchange rates and yield rates. Further, the price of the Underlying Commodity itself depends on a number of interrelated factors, including economic, financial and political events around the world, including factors affecting capital markets and commodity markets generally and the commodity exchanges on which the Underlying Commodity has its primary listing. The price at which a Certificateholder will be able to sell Certificates prior to the Early Termination Date or Expiration Date may be at a discount, which could be substantial, to the value of the Certificates at the Issue Date, if, at such time, the price of the Commodity is equal to or not sufficiently above the price of the Commodity at the Issue Date.

3. Liquidity

The Issuer cannot provide any assurances as to how the Certificates will trade in the secondary market or whether such market will be liquid or illiquid. Application has been made to list the Certificates on SWX Swiss Exchange. No assurance can be given that there will be a market for the Certificates. If the Certificates are not traded on any exchange, pricing information for the Certificates may be more difficult to obtain, and the liquidity and prices of the Certificates may be adversely affected.

4. Conflicts of interest

Potential conflicts of interest may exist between the Calculation Agent and Certificateholders, including with respect to certain determinations and judgements that the Calculation Agent may make pursuant to the Conditions that may influence the amount receivable upon settlement of the Certificates.



Investors should consult their own business, tax, legal and accounting advisors with respect to this proposed transaction and they should refrain from entering into a transaction with us unless they have fully understood the associated risks and have independently determined that the transaction is appropriate for them.